Submitted by jkegerize on
ACLA Comment for USCDI v6: Unique Device Identifier (UDI)
The American Clinical Laboratory Association (ACLA) appreciates the opportunity to comment on the applicable vocabulary standard, FDA Unique Device Identification (UDI) System.
ACLA supports improvements to interoperability infrastructure that will increase patient safety. However, there will be some major challenges with ensuring high quality UDI data is broadly available. The first is the limited use of UDI data in most clinical encounters and settings. Providers do not currently factor UDI information into the clinical decision-making process as it is not a critical piece of information for treatment decisions. The required inclusion of non-pertinent information to a test result can slow down the decision process and adds costs to interoperability support and implementations. Furthermore, existing LIS platforms may not broadly support the inclusion of UDI information with a test result. Updating these LIS systems can be expensive and time consuming while having limited impact on patient treatment decisions. ACLA is concerned that the inclusion of UDI in USCDI version 7 will not lead to broad adoption with high-quality data.
This is not currently supported by most laboratories and would have an impact on the technology and operational aspects. We suggest that ASTP work with FDA, CMS/CLIA, public health agencies, laboratories, and instrument manufacturers to establish a practical roadmap.







Submitted by melanie.kourba… on
Update Usage Note
APHL suggests updating the usage note to: "This element can support the identification of the type of medical device, or the specific medical device used in a patient encounter. The device type is used for higher-level categorization of medical devices. When including the production identifier(s), this element identifies the specific medical device used for that patient, procedure, and/or performed lab tests."